[Evaluation of atherogenic risk in homozygous sickle cell disease: study of lipid and apolipoprotein AI and B plasma levels].
The main clinical use of measurements of Apo Al and Apo B is to determine a patient's risk status for the development of ischemic heart disease. Apo B is generally accepted as a contributory cause of coronary artery disease, while Apo Al apparently has a protective effect. The present study reports the plasma change of Apo Al and B in sickle cell anaemic subjects. Immunochemical findings revealed that Apo Al and B levels were found to be lower in sickle cell patients as compared with normal subjects (HbAA). The atherogenicity index given by Apo B/Apo Al remained in the normal range during periods of steady state (0.64 +/- 0.28), while subjects in painful crisis had high index values (0.95 +/- 0.35). Therefore, we concluded that epidemiological studies on a large sample of patients are needed to confirm this relationship between painful crisis and risk of developing coronary artery disease.
Monnet
P D
PD
Laboratoire de biochimie faculté de pharmacic, Abidian, Côte d'Ivoire.
Kane
F
F
Konan-Waidhet
D
D
Akpona
S
S
Kora
J
J
Diafouka
F
F
Sess
D
D
Sangare
A
A
Yapo
A E
AE
D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood* / Q000150:complications*; D016632:Apolipoprotein A-I / Q000097:blood*; D001055:Apolipoproteins B / Q000097:blood*; D001161:Arteriosclerosis / Q000209:etiology*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D007560:Cote d'Ivoire; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D012307:Risk Factors
D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008055:Lipids
Evaluation du risque athérogène chez le drépanocytaire homozygote: étude des taux plasmatiques des lipides et apolipoprotéines AI et B.